Zobrazeno 1 - 10
of 569
pro vyhledávání: ''
Autor:
Wei, Zhang, Pengbo, Deng, Tiandong, Kong, Bo, Zhang, Fangfei, Qian, Yu, Dong, Ya, Chen, Lu, Chen, Danna, Liu, Yanwei, Zhang, Huaping, Yang, Baohui, Han
Publikováno v:
Lung Cancer. 173:43-48
Extensive stage small cell lung cancer (ES-SCLC) is associated with poor prognosis. Recently, anlotinib has demonstrated significant clinical activity as a third-line or further on treatment. This study aimed to evaluate the safety and efficacy of a
Autor:
de Rooij, Belle H, van den Hurk, Corina, Smaardijk, Veerle, Fernandez-Ortega, Paz, Navarro-Martin, Arturo, Barberio, Lidia, Guckenberger, Matthias, Schmid, Severin, Walraven, Iris, Vallow, Susan, Kotsi, Christina, Preusser, Matthias, Mosor, Erika, Klok, Jente M, Becker, Annemarie, Milani, Alessandra, Ninov, Lyudmil, van de Poll-Franse, Lonneke V
Publikováno v:
Lung Cancer, 173, 5-13. Elsevier Ireland Ltd
de Rooij, B H, van den Hurk, C, Smaardijk, V, Fernandez-Ortega, P, Navarro-Martin, A, Barberio, L, Guckenberger, M, Schmid, S, Walraven, I, Vallow, S, Kotsi, C, Preusser, M, Mosor, E, Klok, J M, Becker, A, Milani, A, Ninov, L & van de Poll-Franse, L V 2022, ' Development of an updated, standardized, patient-centered outcome set for lung cancer ', Lung Cancer, vol. 173, pp. 5-13 . https://doi.org/10.1016/j.lungcan.2022.08.021
Lung Cancer, 173, 5-13
Lung Cancer, 173, pp. 5-13
Dipòsit Digital de la UB
Universidad de Barcelona
de Rooij, B H, van den Hurk, C, Smaardijk, V, Fernandez-Ortega, P, Navarro-Martin, A, Barberio, L, Guckenberger, M, Schmid, S, Walraven, I, Vallow, S, Kotsi, C, Preusser, M, Mosor, E, Klok, J M, Becker, A, Milani, A, Ninov, L & van de Poll-Franse, L V 2022, ' Development of an updated, standardized, patient-centered outcome set for lung cancer ', Lung Cancer, vol. 173, pp. 5-13 . https://doi.org/10.1016/j.lungcan.2022.08.021
Lung Cancer, 173, 5-13
Lung Cancer, 173, pp. 5-13
Dipòsit Digital de la UB
Universidad de Barcelona
Contains fulltext : 287919.pdf (Publisher’s version ) (Open Access) BACKGROUND: In 2016, the International Consortium for Health Outcomes Measurement (ICHOM) defined an international consensus recommendation of the most important outcomes for lung
Autor:
Georgios Stamatis, Gunda Leschber, Birte Schwarz, Diana Lütke Brintrup, Sarah Flossdorf, Bernward Passlick, Erich Hecker, Christian Kugler, Martin Eichhorn, Thomas Krbek, Stephan Eggeling, Rudolf Hatz, Michael Rolf Müller, Sven Hillinger, Clemens Aigner, Karl-Heinz Jöckel
Publikováno v:
Lung Cancer. 172:108-116
Objectives: The oncological equivalence of anatomical segmentectomy for early stage non-small cell lung cancer (NSCLC) is still controversial. Primary aim of this study was survival outcomes in combination with improved quality of life after segmente
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
Juliette Mainguene, Clémence Basse, Philippe Girard, Sophie Beaucaire-Danel, Kim Cao, Emmanuel Brian, Madalina Grigoroiu, Dominique Gossot, Marie Luporsi, Loïc Perrot, Thibault Vieira, Raffaele Caliandro, Catherine Daniel, Agathe Seguin-Givelet, Nicolas Girard
Publikováno v:
Lung Cancer. 163:51-58
Stage IIIA/B-N2 is a very heterogeneous group of patients and accounts for one third of NSCLC at diagnosis. The best treatment strategy is established at a Multidisciplinary Tumor Board (MTB): surgical resection with neoadjuvant or adjuvant therapy v
Autor:
Ruth Plummer, Hendrik-Tobias Arkenau, Jordi Ferrer-Playan, Jason M. Melear, Alexander I. Spira, Ivan Diaz-Padilla, Giuseppe Locatelli, Jennifer Dong, Thomas Goddemeier, Ki Y. Chung, Emma Dean, Patricia Fleuranceau-Morel, Charles H. Redfern, Geoffrey I. Shapiro
Publikováno v:
Lung Cancer. 163:19-26
Objectives Berzosertib (formerly M6620, VX-970) is an intravenous, highly potent and selective, first-in-class ataxia telangiectasia and Rad3-related (ATR) protein kinase inhibitor. We assessed the safety, tolerability, preliminary efficacy, and phar
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Dong Xie, Lihong Qiu, Lei Zhang, Fang Wang, Jiani Gao, Yuming Zhu, Guowei Ma, Chao Li, Xiaomeng Dou, Gening Jiang, Chang Chen, Li Zhixin
Publikováno v:
Lung Cancer. 159:135-144
Objectives To compare the perioperative and oncologic outcomes following pneumonectomy performed by uniportal video-assisted thoracoscopic surgery (U-VATS) and thoracotomy in patients with centrally located non–small cell lung cancer (NSCLC). Mater
Autor:
Jérôme Doyen, Joël Castelli, Enrique Chajon, F. Thillays, Hervé Lena, Pierre-Yves Bondiau, Stéphane Supiot, R. de Crevoisier, Charles Ricordel, Loig Vaugier, Line Claude, J. Bellec, L. Duvergé
Publikováno v:
Lung Cancer. 157:100-108
The duration of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) may affect patient outcomes. We aimed to determine the impact of a continuous versus discontinuous SBRT schedule on local control (LC) and overal
Autor:
Xiaofei Wang, Laurie E. Gaspar, Everett E. Vokes, Junheng Gao, R.U. Komaki, Michael C. Dobelbower, Jeffrey A. Bogart, J. Heymach, Gregory A. Masters, Thomas E. Stinchcombe, Charles Kuzma
Publikováno v:
Lung Cancer
Introduction The CALGB 30610/RTOG 0538 randomized trial was designed to test whether high-dose thoracic radiotherapy (TRT) would improve survival compared with 45 Gy twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC). Two piloted e